T-Detect„¢ Lyme, A New T-Cell Clinical Test For Early Detection Of Lyme Disease, Is Unveiled By Adaptive Biotechnologies
CIOReview
CIOREVIEW >> Pharma & life sciences >>

T-Detect„¢ Lyme, A New T-Cell Clinical Test For Early Detection Of Lyme Disease, Is Unveiled By Adaptive Biotechnologies

By CIOReview | Monday, July 4, 2022

T-Detect Lyme allows patients and healthcare providers to detect Lyme disease earlier and more accurately than current antibody tests.

FREMONT, CA: Diagnosis can improve the efficacy of therapy and help the infected patient avoid long-term consequences. Early detection can aid in the prevention or control of an outbreak. Diagnostic testing can evaluate whether or not antibiotics are an appropriate treatment. Adaptive Biotechnologies Corporation unveils T-Detect„ Lyme. This commercial-stage biotechnology business intends to integrate the genetics of the adaptive immune system into clinical products to detect and treat disease. 

T-Detect detects immunological responses by utilizing the body's specific T-cell response to disease-associated antigens. T-Detect Lyme is a simple blood test designed to aid in the detection of early Lyme disease in adult patients who exhibit signs and symptoms. T-Detect Lyme detects T cells triggered by Borrelia burgdorferi, the bacteria that causes Lyme disease, to aid in the early detection of the condition.

“The T-Detect franchise leverages the immune systems natural abilities and the exquisite specificity of T cells to detect disease early. The availability of T-Detect Lyme may help shorten the time to accurate diagnosis for patients with early Lyme disease. Also, the addition of T-Detect Lyme will support scaling clinical operations to enable our growing T-Detect portfolio, including testing in autoimmune disorders with high unmet need. T-Detect Lyme has demonstrated greater sensitivity than serology in early Lyme disease and may aid in the early diagnosis of up to two times more cases that may be missed by traditional serology testing. We aim to further improve the test sensitivity over time using new data sets from additional individuals to be able to help more patients.” says Sharon Benzeno, Ph.D., the chief commercial officer of Adaptive Biotechnologies.